HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: L'Oreal/Maybelline merger

This article was originally published in The Rose Sheet

Executive Summary

L'Oreal/Maybelline merger: Joh. A. Benckiser GmbH notifies Maybelline that it is seeking U.S. government approval to acquire shares of Maybelline common stock "in a number presently unknown," but sufficient to hold a majority stake in the firm, according to Maybelline's Jan. 25 14D-9 filing with the Securities and Exchange Commission. The estate of Albert Reimann has filed for approval with the Federal Trade Commission and the Assistant Attorney General to surpass the $15 mil. and 50% common stock purchase threshold, which would make the acquisition subject to the Hart-Scott-Rodino Antitrust Improvement Act. Benckiser is an entity of the Reimann estate. Benckiser's announcement follows Maybelline's Jan. 22 statement that it has accepted L'Oreal S.A.'s offer to acquire the firm for $44 a share, or about $610 mil. Benckiser had previously put in a $42 a share bid for Maybelline. L'Oreal said Feb. 2 that it extended the expiration date of its cash tender offer to Feb. 9 at the request of DOJ...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS002458

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel